Mitchell F. Brin

Consensus Statement of the Movement Disorder Society on Tremor

A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein

OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program

Therapeutic Uses of Botulinum Toxin

BOTULINUM TOXIN TYPE A IS A SAFE AND EFFECTIVE TREATMENT FOR NEUROGENIC URINARY INCONTINENCE: RESULTS OF A SINGLE TREATMENT, RANDOMIZED, PLACEBO CONTROLLED 6-MONTH STUDY

Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled Trial

Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A–resistant cervical dystonia

Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology

Idiopathic cervical dystonia: Clinical characteristics

Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm

Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): A 12‐year experience in more than 900 patients